Conventional methods of 2D cell culture have limitations. They do not completely mimic the 3D tissues and organs of the human body. 3D bioprinting offers a way to generate 3D cultures in forms of spheroids (from cancer cells) and embryoid bodies (from stem cells). 3D cell culture is able to better mimic the in vivo conditions of human tissues and organs. Spheroids behave similar to tumors and make good cancer models for studying oncology and testing drugs. Embryoid bodies from stem cells mimic the development of embryos and can be used to study the effects of drugs on the three germ layers of the body – ectoderm, endoderm and mesoderm. The hanging-drop method, a manual generation of such 3D cell structures, is labor-intensive and not amenable to up-scaling in biotech industry.
This technology overcomes the forementioned limitations by offering an automated, cost-effective, novel bioprinter that can rapidly generate 3D cultures of various cell types with multiple applications in drug discovery, cosmetic testing, tumor studies etc. Unlike existing technologies that generate structural parts, this bioprinter can produce functional components like organoids and embryoids, which can be further developed into functional tissues. This feature offers means to create artificial yet biologically-relevant functional tissues.
This bioprinter is developed in-house and extensively tested out over three years. Target users are cell culture researchers and companies engaging in clinical trials of novel drugs and vaccines. Partners are sought for technology development and commercialization collaborations, including 3D bioprinting solution providers, robotics industry, clinical trial companies etc.
Key Biological Innovations: